Efficacy of AVT04, a Biosimilar to Ustekinumab, in Managing Plaque Psoriasis: Findings from a 28-Week Real-World Study - Top-Institutions - MDSpire

Efficacy of AVT04, a Biosimilar to Ustekinumab, in Managing Plaque Psoriasis: Findings from a 28-Week Real-World Study

  • By

  • Edoardo Mortato

  • Marina Talamonti

  • Lorenzo Savastano

  • Lorenzo Marcelli

  • Lorenzo Tofani

  • Valerio Gneo

  • Domenico Marrapodi

  • Maria Rosa Ingrosso

  • Luca Bianchi

  • Marco Galluzzo

  • March 13, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Pharmacology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Rheumatology
    • Immunology

  • #3

    King's College London, St John's Institute of Dermatology
    King's College London, St John's Institute of Dermatology

    London, N/A

    Key Differentiators

    • Dermatology
    • Clinical Immunology

  • #4

    National Psoriasis Foundation Research Center at Northwestern University
    National Psoriasis Foundation Research Center at Northwestern University

    Chicago, IL

    Key Differentiators

    • Dermatology
    • Psoriasis Research

  • #5

    Charité – Universitätsmedizin Berlin
    Charité – Universitätsmedizin Berlin

    Berlin, N/A

    Key Differentiators

    • Dermatology
    • Immunology
    • Health Economics

Original Source(s)

Efficacy of AVT04, a Biosimilar to Ustekinumab, in Managing Plaque Psoriasis: Findings from a 28-Week Real-World Study

  • by Edoardo Mortato, Marina Talamonti, Lorenzo Savastano, Lorenzo Marcelli, Lorenzo Tofani, Valerio Gneo, Domenico Marrapodi, Maria Rosa Ingrosso, Luca Bianchi, Marco Galluzzo

  • March 13, 2026

Related Content

Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial

GLP-1 Agents May Reduce Psoriasis Severity

National Psoriasis Foundation review highlights limited evidence and potential metabolic links.

Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation